Reference Tool
Compare Compounds
Place up to three reference compounds side by side to compare their molecular profile, pharmacokinetics, and handling.
| Attribute | cagrilintide | semaglutide | tirzepatide |
|---|---|---|---|
| Field of Medicine | Endocrinology · Metabolic Research | Endocrinology · Metabolic Research | Endocrinology · Metabolic Research |
| Category | incretin | incretin | incretin |
| Formula | — | C187H291N45O59 | C225H348N48O68 |
| Molecular Weight | ~3800 Da | 4113.6 Da | 4813.5 Da |
| Sequence | Long-acting amylin analog | 31-amino-acid GLP-1 analog with C18 fatty diacid | 39-amino-acid peptide with C20 fatty diacid moiety |
| CAS Number | — | 910463-68-2 | 2023788-19-2 |
| Half-Life | ~7–8 days | ~7 days | ~5 days (preclinical / published clinical literature) |
| Route (research) | Subcutaneous in research models | Subcutaneous in research models | Subcutaneous in research models |
| Onset / Steady-state | — | Steady-state after ~4–5 weeks of weekly dosing | Steady-state typically reached after ~4 weeks of weekly dosing |
| Lyophilized Storage | −20°C long term; 2–8°C short term (weeks). Protect from light. | −20°C long term; 2–8°C short term (weeks). Protect from light. | −20°C long term; 2–8°C short term (weeks). Protect from light. |
| Reconstituted Storage | 2–8°C, generally up to 14–28 days depending on compound. | 2–8°C, generally up to 14–28 days depending on compound. | 2–8°C, generally up to 14–28 days depending on compound. |